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Abstract
Background: Antisense oligomer induced exon skipping aims to reduce the severity of Duchenne muscular
dystrophy by redirecting splicing during pre-RNA processing such that the causative mutation is by-passed and a
shorter but partially functional Becker muscular dystrophy-like dystrophin isoform is produced. Normal exons are
generally targeted to restore the dystrophin reading frame however, an appreciable subset of dystrophin mutations
are intra-exonic and therefore have the potential to compromise oligomer efficiency, necessitating personalised
oligomer design for some patients. Although antisense oligomers are easily personalised, it remains unclear
whether all patient polymorphisms within antisense oligomer target sequences will require the costly process of
producing and validating patient specific compounds.
Methods: Here we report preclinical testing of a panel of splice switching antisense oligomers, designed to excise
exon 25 from the dystrophin transcript, in normal and dystrophic patient cells. These patient cells harbour a single
base insertion in exon 25 that lies within the target sequence of an oligomer shown to be effective at removing
exon 25.
Results: It was anticipated that such a mutation would compromise oligomer binding and efficiency. However, we
show that, despite the mismatch an oligomer, designed and optimised to excise exon 25 from the normal
dystrophin mRNA, removes the mutated exon 25 more efficiently than the mutation-specific oligomer.
Conclusion: This raises the possibility that mismatched AOs could still be therapeutically applicable in some cases,
negating the necessity to produce patient-specific compounds.
Background
Antisense oligomer (AO) induced exon skipping has
emerged as a promising approach to reduce the severity
of Duchenne Muscular Dystrophy (DMD), progressing
rapidly from concept to the completion of several clinical
trials [1-4]. This therapy uses AOs to modify splicing
during pre-RNA processing, such that a DMD-associated
exon is removed and a shorter but partially functional
Becker muscular dystrophy (BMD)-like dystrophin iso-
form is produced. Most commonly, splice switching AOs
are designed to target motifs in the normal dystrophin
gene transcript, which is appropriate, since the most
common type of DMD mutation is a deletion of one or
more exons and it is the normal exon, flanking the dele-
tion that must be removed to restore the reading frame.
In addition, it may be assumed that normal exons will
generally be more difficult to dislodge than a mutated
counter-part, since the full complement of splicing motifs
will be present in the former.
Disease-causing gene lesions, silent polymorphisms or
small intra-exonic deletions, insertions or substitutions
may occur within the oligomer annealing region, or
impact upon splice control motifs. These could poten-
tially alter the efficacy of an AO designed and optimised
for the normal dystrophin gene transcripts. Data from
the Human Genome Project suggests that single nucleo-
tide polymorphisms (SNPs) occur every 100-300 bases
http://www.ornl.gov/sci/techresources/Human_Genome/
faq/snps.shtml. Although the distribution of these SNPs
is non-random, their incidence means that patients may
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exons are, on average, only 150 bp long and splice
switching AOs are designed as 25-32mers, patients car-
rying intra-exonic disease-causing mutations will have
an approximately 1 in 6 chance that the gene lesion will
occur within the AO annealing sequence. Consequently,
even DMD boys with the “same” mutation at the mRNA
level (e.g. a genomic deletion of exon 50) will almost
certainly have unique dystrophin genes because of dif-
ferences in disease-associated deletion break-points, as
well as non-disease associated DNA variations in both
protein-coding and non-coding regions. It should not be
unexpected that each DMD boy could respond to
induced exon skipping in a unique manner. For this rea-
son, the development of optimal exon skipping strate-
gies for most DMD mutations are best evaluated in cells
from the patient.
Subtle dystrophin gene changes, such as intra-exonic
insertion/deletions/substitutions collectively represent
less than 30% of cases but are spread across the dystro-
phin gene, making them a lower priority for immediate
clinical development than amenable mutation sub-types
in the deletion hotspots. In anticipation of accelerated
development of oligomer induced exon skipping as a
therapy for DMD, we wish to develop effective exon
skipping strategies for as many different DMD muta-
tions as possible. As described by Wilton et al [5], we
have optimised AOs to exclude each of the exons in the
dystrophin transcript, excluding the first and last exons,
and are now focused upon further refining AO design
during pre-clinical testing in DMD patient cell lines.
Here we present the optimization of oligomers to skip
exon 25, and report the unexpected finding that a mis-
matched oligomer induced efficient exon exclusion in
cells from a young patient, wit has i n g l eb a s ei n s e r t i o n
in exon 25 (c.3385 Insertion A) that lies within the opti-
mized AO target sequence.
Methods
AO design and synthesis
Oligomers consisting of 2’-O-methyl (2OMe) modified
bases on a phosphorothioate backbone were synthesized
on an Expedite 8909 synthesizer (Applied Biosystems,
Melbourne, Australia), as described by Adams et al. [6].
AO sequences are shown in Table 1 (AO nomenclature
according to Mann et al [7]). The optimal sequence to
excise exon 25 was then prepared and supplied by AVI
Biopharma Inc (Bothell, WA) as a phosphorodiamidate
morpholino oligomer (PMO) conjugated to a cell-pene-
trating peptide (PPMO-k) [8,9].
Cell Culture and Transfection
Normal human myoblasts were prepared as described by
Rando et al. [10] from de-identified muscle biopsies,
obtained with informed consent during elective surgery
in the Department of Neuropathology at Royal Perth
Hospital. Similarly donated after informed consent, de-
identified fibroblasts were obtained from a DMD patient
harbouring a frame shifting mutation in exon 25 (c.3385
Insertion A). Fibroblasts were cultured in DMEM (Invi-
trogen, Melbourne, Australia) supplemented with 20%
foetal calf serum (FCS) (Serana, Bunbury, Australia), 1%
GlutaMax™-I (Gibco, Melbourne, Australia), 10 U/ml
penicillin (Invitrogen), 10 mg/ml streptomycin (Invitro-
gen), and 250 ng/ml amphotericin B (Sigma, Sydney,
Australia). Fibroblasts were converted to myoblasts
through forced myogenesis by transfection with a MyoD
expressing adenovirus [11] and then differentiated in
low serum media. Briefly, patient fibroblasts were cul-
tured to 80% confluency, washed with PBS, detached
with 0.25% Trypsin (w/v) (Gibco), inactivated with
media containing 10% FCS, pelleted by centrifugation at
600 × g and then resuspended in DMEM supplemented
with 5% horse serum and the MyoD adenoviral vector
at a multiplicity of infection of 250. Ninety six hours
after treatment with the MyoD adenoviral vector the
fibroblasts were transfected with AO. The use of human
tissue was approved by the University of Western Aus-
tralia Human Ethics Committee (approval number RA/
4/1/2295).
Normal myoblasts were proliferated and differentiated
as described previously by Harding et al.[ 1 2 ] .A l lc e l l s
were plated at 2 × 10
4 cells/well in 24 well plates that
had been sequentially pre-treated for 1 hour with 50 μg/
ml poly D-lysine (Sigma) and 100 μg/ml Matrigel (BD
Biosciences, Sydney, Australia).
2OMeAOs were transfected as lipoplexes with Lipo-
fectamine 2000
® (1:1 w/w) (Invitrogen) in Opti-MEM
media (Gibco) as per the manufacturer’s instructions.
PPMO-k solutions were warmed for 5 minutes at 37°C
before being diluted in Opti-MEM media as indicated
and applied directly to the adherent cells.
RNA extraction and nested RT-PCR
Total RNA was harvested 96 h after transfection from
duplicate wells using TRIzol
® (Invitrogen) according to
the manufacturer’s instructions, and resuspended in 30
μl of sterile water (Baxter Healthcare, Sydney, Austra-
lia). Approximately 100 ng of total RNA was used as
Table 1 Oligomer Sequences
Oligomer Sequence (5’ to 3’)
H25A(+10+33) UGG GCU GAA UUG UCU GAA UAU CAC
H25A(+95+119) UUG AGU UCU GUC UCA AGU CUC GAA G
H25A(+95+A+119) UUG AGU UCU GUU CUC AAG UCU CGA AG
H25D(+16-08) GUC UAU ACC UGU UGG CAC AUG UGA
H25D(+06-14) GAG AUU GUC UAU ACC UGU UG
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®
III One-step RT-PCR system with Platinum Taq (Invi-
trogen) to amplify exons 13 to 27. After 35 cycles
(myoblasts) and 40 cycles (MyoD converted fibroblasts)
a1μL aliquot was removed and subjected to nested
PCR to amplify exons 18 to 26 for 30 cycles (myo-
blasts) or 35 cycles (MyoD converted fibroblasts),
using AmpliTaq Gold (Applied Biosystems). Details of
PCR primers (Geneworks, Adelaide, Australia) are
s h o w ni nT a b l e2 .
Gel Analysis, Imaging and Sequencing
PCR products were resolved on 2% agarose gels in TAE
buffer and relative exon skipping efficiency estimated by
densitometry of the full length and AO induced PCR
products on images captured by the Chemi-Smart 3000
system (Vilber Lourmat, Marne-la-Vallée, France) as
described previously [6]. Where necessary, the identity
of induced transcripts was confirmed by band stab isola-
tion [13], purification of templates using UltraClean spin
columns (MoBio, Carlsbad, CA) and DNA sequencing
using BigDye V3.1 terminator chemistry (Applied Bio-
systems) as per manufacturer’s instructions. Sequencing
was conducted at the Lotterywest State Biomedical
Facility Genomics (Perth, Australia).
Western analysis of dystrophin expression
Western blotting was performed using a protocol
derived from Cooper et al [14] and Nicholson et al [15].
Cells were harvested by trypsinisation, 7 days after
transfection and placed in treatment buffer (100 μl/4.5
mg wet pellet weight) consisting of 125 mM Tris-HCl
pH 6.8, 15% SDS, 10% glycerol, 0.5 mM PMSF, 50 mM
dithiothreitol, bromophenol blue (0.004% w/v) and a
protease inhibitor cocktail (15 μl/500 μl of treatment
buffer) (Sigma). Samples were vortexed briefly, sonicated
for 1 second, 4-8 times at a setting of 30/100 on an
ultrasonic processor (Sonics, Newtown, CT) and heated
at 95°C for 5 minutes. Samples were then electrophor-
esed at 16°C on a 3-10% Tris- Bis/Glycine SDS gradient
gel at pH 8.8 with a 3% stacking gel pH 6.8. Gel con-
tents were electrophoretically transferred to a Fluoro-
transW PVDF membrane (Pall, Melbourne, Australia)
overnight at 18°C at 290 mA in a transfer buffer without
methanol. Dystrophin was detected with NCL-DYS2
monoclonal anti-dystrophin (Novocastra, Newcastle-
u p o n - T y n e ,U K )a p p l i e da tad i l u t i o no f1 : 1 0 0f o r2
hours at room temperature. Detection was performed
using a Western Breeze kit as per the manufacturer’s
instructions (Invitrogen). Enhanced Chemiluminescence
reactions were detected directly by the Chemi-Smart
3000 gel documentation system (Vilber Lourmat), using
Chemi-Capt software for image acquisition and Bio-1D
software for image analysis.
Results
The splice motif predictor programs, ESE finder [16],
and Rescue ESE [17] were used to predict putative exo-
nic splicing enhancers (ESEs) in exon 25 (Figure 1).
Annealing co-ordinates of AOs relative to the predictive
ESE positions are indicated.
2OMeAOs designed to target the predicted splicing
motifs in dystrophin exon 25 (Table 1 and Figure 1)
were transfected into normal human myoblasts (Figure
2A). In normal cells, all AOs tested demonstrated robust
skipping of exon 25 at 100 nM and were effective at the
lower concentration of 2.5 nM.
Figure 2B shows the levels of exon 25 skipping in
MyoD converted patient fibroblasts after treatment with
the same panel of AOs. H25D(+16-08) and H25D(+06-
14), targeting the exon 25 donor splice site, did not
induce the same degree of exon skipping efficiency in
the patient cells (Figure 2B). H25A(+10+33) induced
similar levels of exon 25 excision in patient and normal
cells, whereas H25A(+95+119) performed better in
patient cells than in normal cells at all concentrations
tested (Figure 2B and 2C).
H25A(+95+119) targets the region of dystrophin exon
25 that encompasses the causative mutation. Since this
mismatched oligomer generated such effective exon
skipping, we subsequently examined the patient’sm u t a -
tion by direct DNA sequencing and confirmed the origi-
n a ld i a g n o s i so fas i n g l eb a s ei n s e r t i o no fa nA ,1 1 0
bases from the beginning of exon 25 (Figure 3A). This
mutation occurs 11 bases downstream from the 5’ end
of H25A(+95+119), raising questions about how it
might be influencing AO efficacy (Figure 3B and 3C).
To investigate this we then designed a mutation specific
AO to target the same coordinates.
AO H25A(+95+A+119) was produced as a patient-
specific AO with perfect complementarity when anneal-
ing to the patient dystrophin transcript (Figure 3D and
Table 1). Surprisingly, transfection of patient cells with
H25A(+95+A+119) shows that perfect complementarity
is not essential for efficient exon skipping in this case
(Figure 4). Although the additional base makes little dif-
ference when compared to H25A(+95+119) in normal
cells, despite the mismatch (Figure 4A), in the patient
cells H25A(+95+A+119) reduces the efficiency of exon
Table 2 Dystrophin primers used for nested RT-PCR
PCR Exon Direction Sequence (5’ to 3’)
Primary 13 Forward AGC TTC AAG AAG ATC TAG AAC AAG
AAC A
Primary 27 Reverse GCT ATG ACA CTA TTT ACA GAC TC
Secondary 18 Forward GAT ATA ACT GAA GTT CAC AG
Secondary 26 Reverse ATT CGT GCA TCT CTG ATA GAT C
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centrations (Figure 4B).
DMD patient fibroblasts were converted to myoblasts
by forced myogenesis and transfected with H25A(+95
+119)-k (i.e. PPMO-k chemistry). Untreated Myo-D con-
verted DMD fibroblasts, and normal myoblasts were
used as negative and positive controls, respectively. Fig-
ure 5 shows that transfection with H25A(+95+119)-k at
800 nM led to significant skipping of exon 25 from the
dystrophin transcript (Figure 5A), and production of
dystrophin protein (Figure 5B) whereas neither could be
detected in patient forced myogenic cells. Sequencing of
Figure 1 Designing AOs to target ESEs in dystrophin exon 25. ESE finder analysis indicates the location of potential binding sites for the
splicing factors SF2/ASF, SC35, SRp40 and SRp55 in exon 25 (A). Rescue ESE analysis was employed to gauge the activity of predicted exonic
splice enhancers (ESE) (B). The arrow indicates the location of the mutation (c.3385 Insertion A), although this single base insertion made no
difference to the splice motifs predicted by ESE Finder (A) or Rescue ESE (B). Antisense oligonucleotide annealing positions are indicated by the
solid bars below the sequence (B). The specific sequences and exonic annealing co-ordinates of these AOs can be found in Table 1.
Figure 2 2OMeAO mediated excision of dystrophin exon 25 in normal and patient cells. 2OMeAOs designed to excise exon 25 from the
dystrophin transcript were transfected into normal human myoblasts (A) and MyoD adenovirus converted (c.3385 Insertion A) patient myogenic
cells (B). Nested RT-PCR was undertaken across exons 18-26 and densitometry used to quantify the relative levels of full length and exon 25
deleted (Δ25) amplicon in each lane as a measure of exon skipping efficacy. The percentage of exon 25 skipping induced by AOs in both
normal (black line) and patient cells (grey line) is presented (C).
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H25A(+95+119)-k treated patient and control myoblasts
(Figure 5A) confirmed the exclusion of exon 25 from
the amplicon (Figure 5C and 5D).
Discussion
DMD patients with whole exon deletions or duplications
can potentially be treated by excising normal exons that
should occur in a near-normal context. For this reason,
unaffected normal human myoblasts are routinely used
for the development and optimisation of splice-switch-
ing AO sequences, and we have previously shown that
the AOs that are most effective in normal cells are gen-
erally also the most effective in patient cells [18]. How-
ever, we recently reported that some intra-exonic
changes can influence the efficiency of AO-mediated
splice manipulation [19].
A panel of AOs were designed to target human dys-
trophin exon 25 and when applied to patient cells car-
rying a single base insertion, all induced exon 25
excision. This DMD-causing gene lesion did not alter
any exonic splicing motifs, as determined by in silico
analysis, but most unexpectedly H25A(+95+119),
which annealed across the insertion and was therefore
mismatched, induced the most robust exon skipping.
When compared to the profile of exon skipping
induced in normal cells, H25A(+95+119) appeared to
be about twice as effective in the patient cells at all
concentrations tested. Some enhancement of exon
skipping in the patient cells would be due to the now
in-frame, AO induced transcripts no longer being sub-
jected to nonsense mediated decay (NMD). Evasion of
NMD would increase the mRNA half life of the tran-
script missing exon 25, thereby increasing its
Figure 3 Confirmation of the patient dystrophin mutation and the potential effect on AO Annealing. The dystrophin (c.3385 Insertion A)
mutation was confirmed by direct sequencing (A). This mutation occurs within the annealing site of H25A(+95+119) suggesting a number of
potential scenarios for the binding of H25A(+95+119) or H25A(+95+A+119) including; perfect complementarity between H25A(+95+119) and
normal dystrophin mRNA (B), a single base “bulge” in the mRNA when H25A(+95+119) binds to patient mRNA (C), perfect complementarity
between H25A(+95+A+119) and patient mRNA (D) and a single base “bulge” in H25A(+95+A+119) when this oligomer binds to normal mRNA
(E).
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script. Conversely, removal of exon 25 from the nor-
mal dystrophin gene transcript does not disrupt the
reading frame, hence intact and exon 25-deleted tran-
scripts should show similar turnover.
We can only speculate as to why the mismatched H25A
(+95+119) oligomer performed so effectively in the patient
cells in comparison to the mutation specific H25A(+95+A
+119). Previous mismatched oligomer studies by us [20]
and others [21,22], utilized sequences with mismatched
bases but no insertions or deletions within the oligomer:
mRNA duplex. Here, we have an oligomer annealing
across a single base insertion that would presumably loop-
out and/or alter the secondary structure of the pre-mRNA
to further compromise exon recognition and selection.
The exon 25 skipping induced by the patient-specific oli-
gomer was comparable to that generated after transfection
with the originally optimized H25A(+95+119) in normal
cells. We are now re-evaluating oligomer design in our
laboratory and including selected mismatches in well-stu-
died splice switching oligomers to determine if this effect
is unique to this mutation or reflects a more general
mechanism (e.g. miRNA binding of seed sequences in
their target gene transcripts [23]).
Testing of oligomers in patient cells will be the most
appropriate way to determine if patient-specific muta-
tions or polymorphisms compromise AO efficacy, and
in the event of diminished oligomer efficacy, an alterna-
tive sequence should be evaluated. Data reported by us
[20] and others [21,22] have reported that mismatched
AOs compromise exon skipping efficiency and we pre-
dicted that personalizing an oligomer optimized in nor-
mal cells to match the patient sequence would further
enhance efficacy. However, this proved otherwise in the
case presented here. The personalized H25A(+95+A
+119) induced exon skipping in both normal and patient
cells but at markedly lower levels than the mismatched
oligomer designed to the normal dystrophin coordinates.
Figure 4 Comparison of optimised and personalised 2OMeAOs for the excision of Exon 25 in normal and patient cells. The 2OMeAOs
H25A(+95+119) and patient-specific H25A(+95+A+119) were transfected into normal myoblasts (A, C and E) and MyoD adenovirus converted
(c.3385 Insertion A) patient myoblasts (B, D and F) at the concentrations indicated. Nested RT-PCR was undertaken across exons 18-26 and
densitometry used to quantify the levels of full length and exon 25-deleted (Δ25) amplicon in each lane as a relative measure of exon skipping
efficiency. The percentage of exon 25 skipping induced by H25A(+95+119) (black line) and H25A(+95+A+119) (grey line) is presented graphically
for normal (E) and patient cells (F).
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skipping in DMD fibroblasts that had undergone forced
myogenesis with the MyoD adenovirus can be technically
challenging, and we were unable to demonstrate dystro-
phin by Western blotting after treatment with the 2OMe
H25A(+95+119). In order to confirm that the efficacy of
the mismatched oligomer was not chemistry specific,
forced myogenic DMD cells were transfected with the
oligomer sequence prepared as PPMO-k.E f f i c i e n te x o n
skipping and detectable dystrophin protein was induced
after H25A(+95+119)-k treatment, indicating that this
effect could also be achieved with the morpholino oligo-
mer chemistry. We did not contemplate using a custo-
mized PPMO-k for this mutation because of the cost of
the compound and its restricted applicability.
Conclusions
Initially, exon skipping to treat DMD will only be applied
to deletions within mutation hotspots. This is despite the
fact that nearly half of the dystrophin exons are in-frame
and therefore many intra-exonic mutations could be
addressed by single exon skipping. Although many such
Figure 5 PPMO-k H25A(+95+A+119) mediated excision of exon 25 from patient cells. H25A(+95+A+119) synthesized as the PPMO-k
chemistry was transfected into MyoD adenovirus converted patient cells (c.3385 Insertion A). The cells were collected 7 days after transfection
for analysis of dystrophin mRNA (A) and protein (B) levels. Samples from normal myoblasts (Normal) and MyoD converted patient myogenic cells
(Patient) are included for comparison. Sequencing of the predominant PCR products generated from the PPMO-k treated patient cells and
control myoblasts (A) confirmed the normal exon 24/25 boundary in control myoblasts (C) and the exclusion of exon 25 in the PPMO-k treated
patient transcripts (D).
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vention, the incentive to pursue these targets is limited by
the fact that in-frame exons do not restore commonly
encountered exon deletion frame-shifts and intra-exonic
mutations are spread across the gene, with no prominent
hotspots. Furthermore, the presence of intra-exonic muta-
tions or SNPs may increase or decrease exon skipping effi-
cacy by altering splice motifs or directly compromising
oligomer annealing, implying that the patients may require
mutation-specific oligomer design. Toxicology and safety
validation adds significant costs to bringing each AO to
the clinic, and even single base changes (e.g. personalisa-
tion) to approved AO designs will require such validation.
Here we show that this level of personalised medicine may
not be necessary in all cases.
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